Phase III Study of S-877503 in Adult Patients with Attention-deficit/Hyperactivity Disorder -long term extension study-
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Guanfacine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Shionogi
- 21 Jun 2019 Status changed from active, no longer recruiting to completed.
- 12 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Jun 2016 New trial record